Clinical trials: Persistent Asthma
Mild Persistent Asthma
Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.
This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.
- Trial name
- NCT01581710
- Volunteers
- 32 people
- Sponsor
- CHA University
Asthma
A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
The primary objective is to compare the efficacy of Symbicort Single inhaler Therapy with treatment according to conventional best practice in adult patients with persistent asthma.
- Trial name
- PASSION (NCT00628758)
- Testing
- Symbicort TBH - Turbuhaler, beta-II-agonist, inhale steroid
- Where
- 15 sites in Turkey (Türkiye)
- Volunteers
- 430 people
- Sponsor
- AstraZeneca
Asthma
Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma
This study is designed to provide data about the 24 hours FEV1 profile, safety and tolerability of indacaterol/mometasone TWISTHALER device compared to placebo and using fluticasone/salmeterol as an active control.
- Trial name
- NCT00557440
- Testing
- fluticasone propionate/salmeterol, indacaterol maleate / mometasone furoate
- Where
- 6 sites in Belgium, Germany
- Volunteers
- 37 people
- Sponsor
- Novartis
Persistent Asthma
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
The primary objective of this study is to evaluate the efficacy of beclomethasone dipropionate administered via BAI at a dose strength of 40 or 80 mcg per oral inhalation (320 or 640 mcg/day, respectively) compared with placebo…
- Trial name
- NCT02513160
- Testing
- Beclomethasone Dipropionate 640, Beclomethasone dipropionate via 320 mcg BAI, albuterol/salbutamol
- Where
- 75 sites in United States
- Volunteers
- 713 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
The purpose of this study is to see if treatment with a medication called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks.
- Trial name
- MUPPITS-2 (NCT03292588)
- Testing
- Mepolizumab
- Where
- 9 sites in United States
- Volunteers
- 335 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
Effect of Flovent Discus vs QVAR vs Pulmicort Flexhaler on Short Term Growth
Children with mild persistent asthma that have asthma symptoms once or twice a week and use a daily controller, while children with mild intermittent asthma rarely have asthma symptoms and do not use a daily controller.
- Trial name
- NCT01520688
- Testing
- Fluticasone, Budesonide, Beclomethasone, Fluticasone, Beclomethasone, Budesonide, Budesonide, Fluticasone, Beclomethasone
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- West Penn Allegheny Health System
Asthma
A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy for the treatment of subjects aged 12-75 years old…
- Trial name
- NCT00314574
- Testing
- omalizumab (Xolair), corticosteroids, long-acting beta-agonists
- Volunteers
- 850 people
- Sponsor
- Genentech, Inc.
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00772538
- Testing
- tiotropium 5mcg/day
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Boehringer Ingelheim
Asthma
Study of Mometasone Furoate/Formoterol Combination and Fluticasone/Salmeterol in Persistent Asthmatics Previously Treated With Inhaled Glucocorticosteroids (P04139)
The purpose of this study is to evaluate the long-term safety of mometasone furoate/formoterol (MF/F) metered dose inhaler (MDI) 200/10 mcg twice-a-day (BID) and MF/F MDI 400/10 mcg BID and two doses of fluticasone/salmeterol…
- Trial name
- NCT00379288
- Testing
- mometasone furoate combination MDI 200/10 mcg BID, mometasone furoate combination MDI 400/10 mcg BID, Fluticasone/Salmeterol 250/50 mcg BID
- Volunteers
- 404 people
- Sponsor
- Organon and Co
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma.
- Trial name
- NCT01257230
- Testing
- tiotropium Respimat low dose, tiotropium Respimat high dose
- Where
- 66 sites in United States, Chile and 10 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
A substance called immunoglobulin E (IgE), which is naturally produced by our body, has a key role in generating asthma attacks.
- Trial name
- NCT00079937
- Testing
- Omalizumab, Fluticasone
- Where
- 56 sites in United States
- Volunteers
- 628 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults
This study will compare during 12 weeks, two treatment strategies for Initial Maintenance Therapy : fluticasone propionate alone or the salmeterol/fluticasone propionate combination in adults with moderate persistent asthma
- Trial name
- NCT00461500
- Testing
- Salmeterol xinafoate/fluticasone propionate combination, Fluticasone propionate
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Asthma
Open Label Study to Assess Safety and Immunogenicity of Omalizumab Liquid Formulation.
The primary objective of this study is to assess the immunogenic potential of the liquid formulation of omalizumab administered over a period of 6 months in moderate to severe persistent allergic asthma patients 12 years of age…
- Trial name
- NCT00500539
- Testing
- omalizumab
- Where
- 31 sites in United States, Argentina and 1 more
- Volunteers
- 155 people
- Sponsor
- Novartis
Asthma
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once…
- Trial name
- NCT01134042
- Testing
- Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, Fluticasone Propionate Inhalation Powder
- Where
- 71 sites in United States, Germany and 4 more
- Volunteers
- 587 people
- Sponsor
- GlaxoSmithKline
Asthma
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control.
- Trial name
- NCT00264849
- Testing
- Omalizumab, Optimized asthma therapy
- Where
- 17 sites in Belgium, Canada and 15 more
- Volunteers
- 406 people
- Sponsor
- Novartis
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00776984
- Testing
- tiotropium 5mcg/day
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 453 people
- Sponsor
- Boehringer Ingelheim
Asthma
AZISAST Study: AZIthromycin in Severe ASThma Study
The purpose of this study is to evaluate the efficacy, safety and cost-effectiveness of azithromycin as add-on therapy in adult subjects with severe persistent asthma, who remain inadequately controlled despite GINA (2006) step 4…
- Trial name
- AZISAST (NCT00760838)
- Testing
- Azithromycin 250 mg
- Where
- 7 sites in Belgium
- Volunteers
- 109 people
- Sponsor
- University Hospital, Ghent
Persistent Asthma
Cockroach Immunotherapy in Children and Adolescents
Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in…
- Trial name
- CRITICAL (NCT03541187)
- Testing
- German cockroach allergenic extract
- Where
- 11 sites in United States
- Volunteers
- 82 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Asthma
A Study of Safety and Efficacy of CNTO 148 in Patients With Severe Persistent Asthma
The purpose of this study is to evaluate the effectiveness and safety of CNTO 148 (golimumab) in patients with severe persistent asthma.
- Trial name
- NCT00207740
- Testing
- CNTO148
- Where
- 57 sites in United States, Belgium and 9 more
- Volunteers
- 309 people
- Sponsor
- Centocor, Inc.
Asthma
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium…
- Trial name
- NCT01311661
- Testing
- Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily
- Where
- 36 sites in United States, Austria and 4 more
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim